Exelixis | EXEL - Operating Profit


Exelixis reported $268.42M in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Agios Pharmaceuticals USD -110.55M 527K Jun/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Amgen USD 4.68B 65M Sep/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
Bayer EUR 129M 698M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Cytokinetics USD -167.09M 12.08M Sep/2026
Eisai JPY 24.73B 35.04B Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Exelixis USD 268.42M 20.01M Sep/2026
Genmab DKK 407M 182M Jun/2026
Glaxosmithkline GBP 2.13B 166M Sep/2026
Incyte USD -707.47M 1.41B Sep/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
MacroGenics USD -13.85M 19.59M Jun/2026
Merck USD 7.33B 6.49B Sep/2026
Moderna USD 130M 945M Sep/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Novartis USD 5.14B 392M Sep/2026
Pfizer USD 662M 5M Sep/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Sanofi EUR 2.38B 115M Jun/2026
Takeda JPY 205.32B 3.9B Sep/2026
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
Xencor USD -36.6M 41.26M Jun/2026